{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:13:13Z","timestamp":1783041193935,"version":"3.54.6"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Chongqing Dikang Erle Pharmaceutical Co. Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40262-025-01491-7","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T10:35:47Z","timestamp":1741257347000},"page":"573-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of Safety and Pharmacokinetics of DDCI-01, a Phosphodiesterase Type 5 Inhibitor, in Healthy Participants"],"prefix":"10.1007","volume":"64","author":[{"given":"Qian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Shen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Chuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-min","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0493-0929","authenticated-orcid":false,"given":"Zhi-Cheng","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"1491_CR1","doi-asserted-by":"crossref","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1).","DOI":"10.1183\/13993003.00879-2022"},{"key":"1491_CR2","doi-asserted-by":"crossref","unstructured":"Ghofrani HA, Gomberg-Maitland M, Zhao L, Grimminger F. Mechanisms and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2024.","DOI":"10.1038\/s41569-024-01064-4"},{"issue":"14","key":"1491_CR3","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jama.2022.4402","volume":"327","author":"NF Ruopp","year":"2022","unstructured":"Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA. 2022;327(14):1379\u201391.","journal-title":"JAMA"},{"issue":"20","key":"1491_CR4","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N Galie","year":"2005","unstructured":"Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148\u201357.","journal-title":"N Engl J Med"},{"issue":"7","key":"1491_CR5","first-page":"1488","volume":"44","author":"HA Ghofrani","year":"2004","unstructured":"Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004;44(7):1488\u201396.","journal-title":"J Am Coll Cardiol"},{"key":"1491_CR6","doi-asserted-by":"crossref","unstructured":"Li A, Zhu Z, He Y, Dong Q, Tang D, Chen Z, et al. DDCI-01, a novel long acting phospdiesterase-5 inhibitor, attenuated monocrotaline-induced pulmonary hypertension in rats. Pulm Circ. 2020;10(4):2045894020939842.","DOI":"10.1177\/2045894020939842"},{"key":"1491_CR7","unstructured":"NMPA. Guidelines for estimating the maximum recommended starting dose in initial clinical trials for therapeutics in healthy adult volunteers. China; 2012."},{"key":"1491_CR8","unstructured":"FDA. ADCIRCA (tadalafil) tablets Label. 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022332s011lbl.pdf."},{"key":"1491_CR9","unstructured":"FDA. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers: U.S. Food and Drug Administration (FDA); 2009."},{"key":"1491_CR10","unstructured":"FDA. CIALIS (tadalafil) tablets, for oral use. 2003. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021368s20s21lbl.pdf."},{"issue":"27","key":"1491_CR11","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.2174\/138161206778343118","volume":"12","author":"CT Supuran","year":"2006","unstructured":"Supuran CT, Mastrolorenzo A, Barbaro G, Scozzafava A. Phosphodiesterase 5 inhibitors\u2013drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr Pharm Des. 2006;12(27):3459\u201365.","journal-title":"Curr Pharm Des"},{"key":"1491_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105078","volume":"160","author":"A Bhat","year":"2020","unstructured":"Bhat A, Ray B, Mahalakshmi AM, Tuladhar S, Nandakumar DN, Srinivasan M, et al. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. Pharmacol Res. 2020;160: 105078.","journal-title":"Pharmacol Res"},{"issue":"12","key":"1491_CR13","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/aps.2015.118","volume":"36","author":"ZW Gao","year":"2015","unstructured":"Gao ZW, Zhu YT, Yu MM, Zan B, Liu J, Zhang YF, et al. Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model. Acta Pharm Sin. 2015;36(12):1528\u201336.","journal-title":"Acta Pharm Sin"},{"issue":"6","key":"1491_CR14","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/j.1365-2125.2008.03107.x","volume":"65","author":"BH Kim","year":"2008","unstructured":"Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR, et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008;65(6):848\u201354.","journal-title":"Br J Clin Pharmacol"},{"key":"1491_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fendo.2016.00111","volume":"7","author":"F Hannah-Shmouni","year":"2016","unstructured":"Hannah-Shmouni F, Faucz FR, Stratakis CA. Alterations of phosphodiesterases in adrenocortical tumors. Front Endocrinol (Lausanne). 2016;7:111.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"63","key":"1491_CR16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-pharmtox-040122-034745","volume":"20","author":"A Samidurai","year":"2023","unstructured":"Samidurai A, Xi L, Das A, Kukreja RC. Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders. Annu Rev Pharmacol Toxicol. 2023;20(63):585\u2013615.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1\u20133","key":"1491_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejphar.2009.05.020","volume":"615","author":"S Korkmaz","year":"2009","unstructured":"Korkmaz S, Radovits T, Barnucz E, Neugebauer P, Arif R, Hirschberg K, et al. Dose-dependent effects of a selective phosphodiesterase-5-inhibitor on endothelial dysfunction induced by peroxynitrite in rat aorta. Eur J Pharmacol. 2009;615(1\u20133):155\u201362.","journal-title":"Eur J Pharmacol"},{"key":"1491_CR18","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.2147\/DDDT.S308610","volume":"15","author":"H Qian","year":"2021","unstructured":"Qian H, Chen Q, Liang L, Zou Y, Pu H, Xin L, et al. A phase I study to evaluate the safety, tolerability, and pharmacokinetics of TPN171H, a novel phosphodiesterase type 5 inhibitor, in healthy subjects. Drug Des Dev Ther. 2021;15:2947\u201359.","journal-title":"Drug Des Dev Ther"},{"key":"1491_CR19","doi-asserted-by":"crossref","unstructured":"Barnes H, Brown Z, Burns A, Williams T. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev. 2019;1(1):CD012621.","DOI":"10.1002\/14651858.CD012621.pub2"},{"issue":"10","key":"1491_CR20","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1111\/j.1743-6109.2011.02382.x","volume":"8","author":"F Azzouni","year":"2011","unstructured":"Azzouni F, Abusamra K. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. J Sex Med. 2011;8(10):2894\u2013903.","journal-title":"J Sex Med"},{"issue":"1","key":"1491_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/sj.bjp.0704687","volume":"136","author":"TC Bellamy","year":"2002","unstructured":"Bellamy TC, Garthwaite J. Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells. Br J Pharmacol. 2002;136(1):95\u2013103.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1491_CR22","doi-asserted-by":"publisher","first-page":"e520-e6","DOI":"10.1097\/MJT.0000000000000766","volume":"26","author":"S Bhogal","year":"2019","unstructured":"Bhogal S, Khraisha O, Al Madani M, Treece J, Baumrucker SJ, Paul TK. Sildenafil for pulmonary arterial hypertension. Am J Ther. 2019;26(4):e520\u20136.","journal-title":"Am J Ther"},{"key":"1491_CR23","unstructured":"Food, Drug Administration HHS. International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice. Fed Regist. 2010;75(13):3471\u20132."},{"issue":"1","key":"1491_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2125.2006.02726.x","volume":"63","author":"ST Forgue","year":"2007","unstructured":"Forgue ST, Phillips DL, Bedding AW, Payne CD, Jewell H, Patterson BE, et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol. 2007;63(1):24\u201335.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01491-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01491-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01491-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:19:43Z","timestamp":1745939983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01491-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1491"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01491-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"3 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Chongqing Dikang Erle Pharmaceutical Co. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DZ and WZ were Chongqing Dikang Erle Pharmaceutical Co. Ltd. employees at the time the study was conducted. All the authors have no competing interests in relation to the work described.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"RC and ZJ designed the study. QL, SH, and YM recruited patients and were responsible for the informed consent form signing process. SH and YM followed up with patients. QL, DZ, and WZ conducted the data analysis. QL and SH wrote the first draft of the manuscript, and RC and ZJ edited the manuscript. RC and ZJ are the guarantors of this work and, as such, had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}},{"value":"The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Ethics Committee of Peking Union Medical College Hospital (Approval number HS2020053).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written, informed consent was obtained from all participants.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}